PULSE BIOSCIENCES, INC. - 8-K Filing

Pulse Biosciences reports Q3 2026 revenue of $0.4 million and completes enrollment for NANOPULSE-AF U.S. pivotal study. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PLSE

Read the full article at SEC EDGAR

More Regulatory news